Bristol-Myers Squibb still has work to do to resolve its income tax reporting processes, the company acknowledged in a 10-K filed with the Securities & Exchange Commission March 15

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.